TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Imugene ( (AU:IMU) ) just unveiled an update.
Imugene Limited has issued 19,491,635 fully paid ordinary shares to Precision Biosciences, Inc. as part of a milestone achievement under their License Agreement. This issuance reflects Imugene’s progress in its strategic collaboration with Precision Biosciences, potentially enhancing its market position in the immuno-oncology sector. The move signifies Imugene’s commitment to advancing its clinical and commercial milestones, aligning with its vision to become a leader in the rapidly growing global cancer treatment market.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene is a clinical stage immuno-oncology company focused on developing innovative immunotherapies designed to activate the immune system of cancer patients to treat and eradicate tumors. The company’s product pipeline includes an off-the-shelf cell therapy CAR T drug targeting blood cancer, multiple B-cell vaccine candidates, and an oncolytic virotherapy aimed at treating various cancers. Imugene collaborates with international cancer experts to develop new cancer therapies, aiming to transform cancer treatment and improve patient outcomes globally.
YTD Price Performance: -70.99%
Average Trading Volume: 2,758,458
Technical Sentiment Signal: Sell
Current Market Cap: A$108M
Find detailed analytics on IMU stock on TipRanks’ Stock Analysis page.